{Reference Type}: Journal Article
{Title}: The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
{Author}: Skaarup KG;Lassen MCH;Modin D;Johansen ND;Loiacono MM;Harris RC;Lee JKH;Dufournet M;Vardeny O;Peikert A;Claggett B;Solomon SD;Jensen JUS;Biering-Sørensen T;
{Journal}: J Infect
{Volume}: 89
{Issue}: 1
{Year}: 2024 Jul 23
{Factor}: 38.637
{DOI}: 10.1016/j.jinf.2024.106187
{Abstract}: <B>OBJECTIVE: </B>To summarize current evidence of high-dose influenza vaccine (HD-IV) vs standard-dose (SD-IV) regarding severe clinical outcomes.<BR><B>METHODS: </B>A prespecified meta-analysis was conducted to assess relative vaccine effectiveness (rVE) of HD-IV vs SD-IV in reducing the rates of (1) pneumonia and influenza (P&I) hospitalization, (2) all hospitalizations, and (3) all-cause death in adults ≥ 65 years in randomized controlled trials. Pooled effect sizes were estimated using fixed-effects models with the inverse variance method.<BR><B>RESULTS: </B>Five randomized trials were included encompassing 105,685 individuals. HD-IV vs SD-IV reduced P&I hospitalizations (rVE: 23.5 %, [95 %CI: 12.3 to 33.2]). HD-IV vs SD-IV also reduced rate of all-cause hospitalizations (rVE: 7.3 %, [95 %CI: 4.5 to 10.0]). No significant differences were observed in death rates (rVE = 1.6 % ([95 %CI: -2.0 to 5.0]) in HD-IV vs SD-IV. Sensitivity analyses omitting trials with participants sharing the same comorbidity, trials with ≥ 100 events, and random-effects models provided comparable estimates for all outcomes.<BR><B>CONCLUSIONS: </B>HD-IV reduced the incidence of P&I and all-cause hospitalization vs SD-IV in adults ≥ 65 years in randomized trials, through no significant difference was observed in all-cause death rates. These findings, supported by evidence from several randomized studies, can benefit from replication in a fully powered, individually randomized trial.